抑制MEK1 R189素化增强了多塞塔塞尔对多个瘤细胞的化学敏感性
Teng Xue1, Shujia Fei2, Jian Gu2
1Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing 211166, Jiangsu, People's Republic of China.
概括
结合丁氨酸减弱酶 (PADI) 抑制剂与多西 (Doc) 添加抑制多种癌症类型的瘤生长. 这一策略还恢复了耐药细胞对化疗的敏感性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 耐药性仍然是癌症治疗中的一个重大障碍.
- 之前的研究表明,丁丁丁氨基脱胺酶2 (PADI2) 抑制可以提高dcetaxel在特定乳腺癌细胞中的疗效.
- 在各种瘤类型中,PADI2抑制与多塞塔结合的更广泛适用性需要研究.
研究的目的:
- 为了评估PADI抑制剂和多塞 (Doc) 在体外和体内在各种瘤细胞系中联合的抗瘤作用.
- 调查PADI2催化MEK1Arg 189的林化在瘤生长和对治疗的反应中的作用.
- 为了确定这种综合方法是否可以克服化疗耐药性并恢复对多塞塔克塞尔或西斯的敏感性.
主要方法:
- 利用了四个不同的瘤细胞系,具有不同的PADI表达.
- 在体外和体外评估中使用PADI抑制剂 (BB-Cla) 和多塞 (Doc) 组合.
- 分析了MEK1 Arg 189的PADI2催化素化及其对瘤细胞干细胞因子和化疗敏感性的影响.
主要成果:
- PADI抑制和Doc的组合在所有测试的瘤类型中增加抑制了瘤细胞的生长.
- 在所有四个瘤细胞系中观察到MEK1 Arg 189的PADI2催化素化;阻止这种功能增强了Doc的抗瘤作用.
- 抑制MEK1Cit189降低了癌细胞干细胞因子,并在耐药细胞中部分恢复了对多塞塔克塞尔或西斯的敏感性.
结论:
- 将PADI抑制剂与多塞素结合起来,为各种癌症提供了一个有前途的治疗策略.
- 向PADI2催化MEK1素化是一种可行的方法,可以提高抗瘤疗效并克服耐药性.
- 这项研究为开发涉及多塞和PADI抑制剂的新型组合疗法提供了坚实的实验基础.
相关概念视频
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


